• English
  • Eesti

    The second meeting of the Heads of EU Medicines Agencies will be held in Tallinn to discuss the priorities of the medicines sector

    Printer-friendly version

    The second meeting of the network of the Heads of Medicines Agencies (HMA) as steered by the Estonian State Agency of Medicines (SAM) will start tomorrow, on 28 November.

    The meeting brings together more than 100 delegates to discuss issues raised by SAM as part of Estonian Presidency of the Council of the EU. Director General of SAM Kristin Raudsepp outlined the essentials: “In line with previous discussions in the HMA, the meeting will focus on the availability of new innovative medicinal products. This meeting will address how medicines agencies could – through the provision of regulatory and scientific advice - support drug development, how the results of academic research could be better used in the context of marketing authorization applications, and what is the impact of regulatory guidelines on the availability of medicinal products. For instance, some guidance’s on veterinary medicinal products - like requirements to marketing authorization dossiers for medicines classified as MUMS/limited-market, and incident management plans - are subject to review. Such guidelines affect the availability of medicines.

    The strengthening of surveillance to exclude counterfeit medicines from the legal supply chain, implementation of the new system of safety features, and cooperation on laboratory testing of medicinal products continue to remain in focus.

    Further, the agenda features other issues of strategic importance like the impact of Brexit on the surveillance activities and services of the Member States’ medicines agencies, including the new location of the European Medicines Agency (EMA). Plus the development of e-services, the possibilities for optimising regulatory activities, borderline products, and an overview of developments related to the regulation on veterinary medicines.”

    The event includes a discussion on strategic lines of action related to exposure to drugs and medical device exposure.

    The meeting will take place on 28-30 November at Radisson Blu Hotel Olümpia in Tallinn.

    For more information on the HMA working group please visit our website.